MRSA What Are Our Treatment Options and How Do We Choose the Right One?

Size: px
Start display at page:

Download "MRSA What Are Our Treatment Options and How Do We Choose the Right One?"

Transcription

1 MRSA What Are Our Treatment Options and How Do We Choose the Right One? Kristi Traugott, PharmD, BCPS Clinical Pharmacy Specialist Infectious Diseases University Health System San Antonio, TX October 25, 2014 Patient Case 45 yo M with PMH of uncontrolled DM2, HTN, HLP, and obesity comes to ER with complaints of fever to o F, malaise and painful, eyrthematous pustule on his groin. History of multiple pustules he has self-drained over past year in similar area Within a few hours of presentation becomes hypotensive and disoriented ESKAPE Bugs Enterococcus sp Staphylococcus aureus Klebsiella pneumoniae Acinetobacter Psuedomonas Enterobacter/Enterobacteriacae Boucher HW, et al. Clin Infect Dis. 2009;48:1-12 Objectives Describe the epidemiology of methicillin resistant Staphylococcus aureus (MRSA) Identify the available antimicrobials for the treatment of MRSA infections Describe what disease state and patient factors would aid in guidance to the most appropriate treatment of patients with MRSA infections What is MRSA? Methicillin resistant Staphylococcus aureus Gram positive cocci in clusters β hemolytic colonies 1

2 % Methicillin Resistant 11/4/2014 What is MRSA? Methicillin resistant Staphylococcus aureus Causes serious infections Community acquired Hospital acquired EPIDEMIOLOGY Common type of infections Cellulitis/abscesses Bacteremia/endocarditis Pneumonia Staphylococcus Resistance Staphylococcus Resistance Drug Year Introduced Years to Report of Resistance Years Until 25% Resistance in Hospital Years Until 25% Resistance in Community Penicillin Methicillin 1961 < Vancomycin ?? Penicillin resistance β-lactamases Methicillin resistance change target site MecA gene PBP2 to PBP2a Vancomycin resistance change target site VanA, VanB acquired from VRE D-ala D-ala to D-ala D-lactate Chambers HF. Emerg Infect Dis. 2001; 7: Staphylococcus Resistance University Hospital MRSA Rates Year Chambers HF. Emerg Infect Dis. 2001; 7: Internal Data: University Health System 2

3 MRSA Infections CDC Threat Report: CDC Threat Report: Alphabet Soup ANTIMICROBIALS Abbv GNR MRSA VISA VRSA VRE Definition Gram Negative Rod Methicillin Resistant Staphylococcus aureus Vancomycin Intermediate Staphylococcus aureus Vancomycin Resistant Staphylococcus aureus Vancomycin Resistant Enterococcus MRSA Drug Review MRSA Drug Review Antimicrobial Spectrum Route Pearl Vancomycin Telavancin Daptomycin Linezolid Quinupristin/ dalfopristin Gram positive (staph, strep, diphth, peptostrep, actinomyces) NO VRE, VISA, VRSA, GNR Gram positive similar to vanco More potent (VISA?) Gram positive similar to vanco but add VRE, VISA, VRSA Gram positive similar to vanco but add VRE, VISA, VRSA Gram positive inclusing MRSA and VRE (E. faecium ONLY) /PO Mainstay for serious infection Vanco on steroids; lots of AE Muscle toxicity, inactivated by lung surfactant, $$$ Thrombocytopenia, neuropathies, $$$ Myopathies, not used much, $$$ Antimicrobial Spectrum Route Pearl Ceftaroline Clindamycin Doxy/mino Tigecycline Trimeth/sulfa Gram positive (MRSA) + gram negative (NO Pseudomonas) Gram positive (MRSA) + above the diaphragm anaerobes Gram positive (MRSA) + gram negative (NO Pseudomonas) Gram positive (MRSA) + gram negative (NO Pseudomonas) + anaerobes Gram positive (MRSA) + gram negative (NO Pseudomonas) /PO /PO /PO First BL with MRSA activity; vanc + ceftriaxone spectrum,$$ Increasing MRSA resistance; inducible resistance Great MRSA but lack strep coverage Severe N/V; BBW of increased mortality, $$$ Great MRSA but lack strep coverage 3

4 New Gram Positive Agents NEWLY APPROVED GRAM POSITE AGENTS Approval Date Generic Brand Company 5/23/2014 Dalbavancin Dalvance Durata Pharmaceutical 6/20/2014 Tedizolid Sivextro Cubist Pharmaceutical 8/6/2014 Oritavancin Orbactiv The Medicines Company Tedizolid Dalbavancin Oritavancin MOA Tedizolid Protein synthesis inhibitor Spectrum Staph (MRSA, MSSA), Strep, Enterococcus (VRE) Linezolid resistant isolates? Mutations in chromosomal genes encoding 23S rrna or ribosomal proteins (L3 or L4) vs cfr gene Claim to fame? Less toxicity and drug interactions Sivextro [package insert]. Cubist Pharmaceuticals, Lexington, MA; 2014 Tedizolid ESTABLISH TRIALS 4

5 Response Rate (%) 11/4/2014 Tedizolid Efficacy Tedizolid Safety Tedezolid Linezolid Outcome Tedizolid n=331, n(%) ESTABLISH-1 Linezolid n=335, n(%) Tedizolid n=331, n(%) ESTABLISH-2 Linezolid n=327, n(%) 1 AE 135 (40.8) 145 (43.3) 148 (45) 141 (43) Nausea 28 (8.5) 45 (13.4) 26 (8) 36 (11) Headache 21 (6.3) 17 (5.1) 20 (6) 22 (7) Vomiting 9 (2.7) 20 (6.0) 10 (3) 17 (5) Pruitius 3 (0.9) 8 (2.4) Dyspepsia 2 (0.6) 7 (2.1) ESTABLISH-1 ESTABLISH-2 ESTABLISH-1 ESTABLISH-2 Early Clinical Response End of Therapy Prokocimer, et al. JAMA. 2013;309(6): Moran, et al. Lancet Infect Dis. 2014;14: Prokocimer, et al. JAMA. 2013;309(6): Moran, et al. Lancet Infect Dis. 2014;14: Tedizolid Safety Tedizolid Pharmacokinetics Maximum % decrease over 21 days (mean/individual) Dose Platelets (%) Neutrophils (%) Placebo -5/-23-2/ mg tedizolid daily -15/-38-18/ mg tedizolid daily -23/-43-4/ mg tedizolid daily -38/-50-37/ mg linezolid daily -22/-54-38/66 Parameter Tedizolid Linezolid Dose 200 mg daily 600 mg BID Bioavailability 91% 100% Cmax(mcg/mL) T ½ 12 hours 4-5 hours AUC 0-24 (mcg*hr/ml) Protein Binding 70-90% 31% Vd (L) Metabolism Liver; not CYP450 Oxidation (metabolites) Excretion 82% feces, 18% urine 65% non-renal, 30% renal Prokocimer, et al. Presented at: ICACC/IDSA Zyvox [package insert]. Pfizer Inc, NY, NY; 2014 Sivextro [package insert]. Cubist Pharmaceuticals, Lexington, MA; 2014 Tedizolid Pharmacokinetics Tedizolid in Neutropenia Parameter Tedizolid Linezolid Dose 200 mg daily 600 mg BID Bioavailability 91% 100% Cmax(mcg/mL) T ½ 12 hours 4-5 hours AUC 0-24 (mcg*hr/ml) fauc 0-24 (mcg*hr/ml) Protein Binding 70-90% 31% Vd (L) Metabolism Liver; not CYP450 Oxidation (metabolites) Excretion 82% feces, 18% urine 65% non-renal, 30% renal MIC 50 /MIC /0.25 1/2 In granulocytopenic mice (neutrophil count <100 cells/ml), bacterial stasis was achieved at a humanequivalent dose of approximately 2000 mg/day In non-granulocytopenic animals, stasis was achieved at a human-equivalent dose of approximately 100 mg/day The safety and efficacy for the treatment of neutropenic patients have not been evaluated Zyvox [package insert]. Pfizer Inc, NY, NY; 2014 Sivextro [package insert]. Cubist Pharmaceuticals, Lexington, MA; 2014 Prokocimer, et al. Antimicrob Agents Chemother. 2012;56: Sivextro [package insert]. Cubist Pharmaceuticals, Lexington, MA;

6 Response Rate (%) Response Rate (%) 11/4/2014 Tedizolid vs Linezolid Similar spectrum Tedizolid may pick up some linezolid R isolates Less drug interactions Less toxicity? Lower dose Large studies for only 6 days Linezolid goes generic 2015! Dalbavancin/Oritavancin MOA: Lipoglycopeptide antibacterials that inhibit cell wall synthesis and disrupt cell membrane integrity Spectrum Dalbavancin Staphylococcus (MRSA) Streptococcus (Viridans, S. pneumo, beta streps) Enterococcus (vanco susc isolates only) Oritavancin Staphylococcus (MRSA) Streptococcus (Viridans, S. pneumo, beta streps) Enterococcus (vanco susc AND resistant isolates) Discover-1 and Discover-2 Dalbavancin Efficacy Dalbavancin 1g day mg day 8 Vancomycin X 3 days Optional switch to PO linezolid days DISCOVER-1 DISCOVER-2 DISCOVER-1 DISCOVER-2 Dalbavancin Vanc/LZD Early Clinical Response End of Therapy Boucher, et al. New Engl J Med. 2014;370: Boucher, et al. New Engl J Med. 2014;370: SOLO-1 and SOLO-2 Oritavancin Efficacy 100 Oritavancin 1200 mg X Oritavancin Vancomycin Vancomycin X 7-10 days SOLO-1 SOLO-2 SOLO-1 SOLO-2 Early Clinical Response End of Therapy Corey, et al. N Engl J Med. 2014;370: Corey, et al. Presented at: ICAAC 2013 Corey, et al. N Engl J Med. 2014;370: Corey, et al. Presented at: ICAAC

7 Dose Dalbavancin and Oritavancin Pharmacokinetics Parameter Dalbavancin Oritavancin 1000 mg day mg day 8 over 30 min infusion 1200 mg X 1 over 3 hrs Use of UFH is CI for 48 hrs bc aptt remain falsely elevated for ~48hs Cmax(mcg/mL) T ½ 346 hours 245 hours AUC 0-24 (mcg*hr/ml) Protein Binding 93% 85% Vd (L) Shown to artificially prolong PT and INR for up to 24h, making monitoring of warfarin unreliable for up to 24 hours Metabolism Very little None Excretion Feces and urine Feces and urine Drug/Drug Interactions None Yes! Inducer and Inhibitor Drug/Lab Interactions None YES!! Dalbavancin/Oritavancin: Unanswered Questions Gram positive agents with LONG T ½ Change treatment paradigm? Who are these patients? Cost effective? Dalba ~$4500/course, Orita ~$2900 Are there issues with resistance and long term low drug levels? Dalvance [package insert]. Durata Therapeutics, Chicago, IL; 2014 Orbactiv [package insert]. The Medicines Co, Parsippany, NJ; 2014 Liu C, et al. Clin Infect Dis. 2011;52:1-38 CLINICAL INFECTIONS Go to guidelines section Skin and Soft Tissue Infections Non-purulent vs purulent cellulitis Empiric tx: β-hemolytic strep Empiric tx: MRSA Skin and Soft Tissue Infections Incision and drainage is primary treatment if abscess Simple abscesses or boils this alone is adequate Antibiotic therapy recommended: Severe/extensive disease Rapid progression Systemic symptoms Comorbidities/immunosuppression No drainage Lack of response to I&D Don t forget to get cultures!!! 7

8 Skin and Soft Tissue Infections Skin and Soft Tissue Infections Outpatient Inpatient Outpatient Outpatient Clindamycin TMP-SMX ± β-lactam Doxy/mino ± β-lactam Linezolid/tedizolid Vancomycin Linezolid/tedizolid Daptomycin Telavancin Ceftaroline Clindamycin **Consider addition of β-lactam if nonpurulent** Clindamycin Increasing MRSA resistance Inducible resistance C. diff? TMP-SMX ± β-lactam Sulfa allergy? Renal failure? Sun sensitivity Doxy/mino ± β-lactam Sun sensitivity N/V Linezolid/tedizolid Cost, cost, cost, cost Long term-toxicities (linezolid) Skin and Soft Tissue Infections Recurrent MRSA SSTI Inpatient Vancomycin Typical mainstay of therapy Linezolid/tedizolid Easy PO transition Cost, cost, cost Decrease toxin production Daptomycin Cost, cost, cost Skeletal muscle toxicity Inpatient Telavancin Ceftaroline Broader spectrum Clindamycin Decrease toxin production **Consider addition of β-lactam if nonpurulent** Personal hygiene and appropriate wound care Environmental hygiene Decolonization (if recurrent despite above practices) Nasal decolonization mupirocin BID X 5-10 d Body decolonization chlorhexidine or dilute bleach baths Do not treat colonization with antimicrobial therapy Bacteremia and Endocarditis MRSA bacteremia is a BIG DEAL!!! High morbidity and mortality Can cause metastatic infections Endocarditis Epidural abscess Vertebral osteomyelitis Liver/kidney/spleenic abscesses Source identification and control extremely important!! Get follow up cultures!! Bacteremia and Endocarditis Duration of therapy Uncomplicated: at least 2 weeks No endocarditis or prostheses, clearance of blood cultures 2-4d, defervescence w/in 72h, no evidence of metastatic infection Complicated: 4-6 weeks Do not meet above criteria 8

9 Bacteremia and Endocarditis Treatment: vancomycin or daptomycin Vancomycin High trough levels: Daptomycin Non-inferior to standard therapy Development of resistant on daptomycin therapy Use higher doses: 8-10 mg/kg/d Good safety data for higher doses Bacteremia and Endocarditis Treatment Addition of rifampin or low dose gentamicin no longer recommended Rifampin increased duration of bacteremia Gentamicin no clinical benefit with increased risk of nephrotoxicity Daptomycin alone: 7% Vancomycin + gentamicin: 19% Anti staphylococcal penicillin + gentamicin: 17% Fowler VG, et al. N Engl J Med. 2006; 355: Levin DP, et al. Ann Intern Med. 1991; 115: Cosgrove SE, et al. Clin Infect Dis. 2009;48: Bacteremia and Endocarditis Pneumonia Persistent bacteremia Search for and remove foci of infection!!! Susceptible to daptomycin: High dose daptomycin + low dose gentamicin, rifampin, linezolid, TMP-SMX, beta-lactam Reduced susceptibility to vancomycin and daptomycin: Quinupristin-dalfopristin, TMP-SMX, linezolid, telavancin as single agent or combination Ceftaroline? Typical MRSA PNA patient Requires ICU admission, necrotizing or cavitary infiltrates and/or empyema Preceding or concurrent influenza-like illness Frequent colonizer Treatment Vancomycin or linezolid first line Telavancin, ceftaroline, clindamycin, TMP-SMX second line NO DAPTOMYCIN!!! Pneumonia Treatment vancomycin or linezolid Vancomycin Was std of care Poor penetration (trough 15-20) Linezolid Several studies vs vancomycin ZEPHYR trial MRSA nosocomial pneumonia Linezolid superior to vancomycin in clinical success 57.6% vs 46.6%, p = 0.04 No difference for 60 day mortality Never use daptomycin Ceftaroline? Tedizolid?? HOW DO WE PROTECT OURSELVES AND PATIENTS? Wunderink RG, et al. Clin Infect Dis. 2012; 54:

10 Prevention Is Important!! Prevention 24-yo quadriplegic M (traumatic spinal cord injury) found to be colonized with MRSA No history of MRSA infection or colonization Health care worker performed abdominal exam and for infection control demonstration cultured ungloved hand Before alcohol hand sanitizer After alcohol hand sanitizer Donskey CJ, et al. N Engl J Med. 2009;360:e3 Prevention Questions?? Donskey CJ, et al. N Engl J Med. 2009;360:e3 10

Appropriate Antimicrobial Therapy for Treatment of

Appropriate Antimicrobial Therapy for Treatment of Appropriate Antimicrobial Therapy for Treatment of Staphylococcus aureus infections ( MRSA ) By : A. Bojdi MD Assistant Professor Inf. Dis. Dep. Imam Reza Hosp. MUMS Antibiotics Still Miracle Drugs Paul

More information

Antibiotic Updates: Part I

Antibiotic Updates: Part I Antibiotic Updates: Part I Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

Staph Cases. Case #1

Staph Cases. Case #1 Staph Cases Lisa Winston University of California, San Francisco San Francisco General Hospital Case #1 A 60 y.o. man with well controlled HIV and DM presents to clinic with ten days of redness and swelling

More information

New Antibiotics for MRSA

New Antibiotics for MRSA New Antibiotics for MRSA Faculty Warren S. Joseph, DPM, FIDSA Consultant, Lower Extremity Infectious Diseases Roxborough Memorial Hospital Philadelphia, Pennsylvania Faculty Disclosure Dr. Joseph: Speaker

More information

Antimicrobial Therapy

Antimicrobial Therapy Antimicrobial Therapy David H. Spach, MD Professor of Medicine Division of Infectious Diseases University of Washington, Seattle Disclosure: Dr. Spach has no significant financial interest in any of the

More information

Best Antimicrobials for Staphylococcus aureus Bacteremia

Best Antimicrobials for Staphylococcus aureus Bacteremia Best Antimicrobials for Staphylococcus aureus Bacteremia I. Methicillin Susceptible Staph aureus (MSSA) A. In vitro - Anti-Staphylococcal β-lactams (Oxacillin, Nafcillin, Cefazolin) are more active B.

More information

Skin and Soft Tissue Infections Emerging Therapies and 5 things to know

Skin and Soft Tissue Infections Emerging Therapies and 5 things to know 2011 MFMER slide-1 Skin and Soft Tissue Infections Emerging Therapies and 5 things to know Aaron Tande, MD Assistant Professor of Medicine October 27, 2017 Division of INFECTIOUS DISEASES 2011 MFMER slide-2

More information

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines

Antibiotic Abyss. Discussion Points. MRSA Treatment Guidelines Antibiotic Abyss Fredrick M. Abrahamian, D.O., FACEP, FIDSA Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical Center Sylmar, California

More information

Antimicrobial stewardship: Quick, don t just do something! Stand there!

Antimicrobial stewardship: Quick, don t just do something! Stand there! Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger

More information

Antimicrobials Update

Antimicrobials Update Antimicrobials Update Rosie Amini, PharmD. BCPS Antimicrobial Stewardship Program Coordinator Swedish Medical Center Disclosures: Dr. Amini has no significant financial interest in any of the products

More information

Antibacterials. Recent data on linezolid and daptomycin

Antibacterials. Recent data on linezolid and daptomycin Antibacterials Recent data on linezolid and daptomycin Patricia Muñoz, MD. Ph.D. (pmunoz@micro.hggm.es) Hospital General Universitario Gregorio Marañón Universidad Complutense de Madrid. 1 GESITRA Reasons

More information

SKIN AND SOFT TISSUE INFECTIONS OCTOBER 3-4, 2015

SKIN AND SOFT TISSUE INFECTIONS OCTOBER 3-4, 2015 SKIN AND SOFT TISSUE INFECTIONS OCTOBER 3-4, 2015 Disclosures I have no financial conflicts of interest to disclose or report. Steven Tran, PharmD NEFSHP Fall Meeting 2015 Objectives for Pharmacists Review

More information

Other Beta - lactam Antibiotics

Other Beta - lactam Antibiotics Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics

More information

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16

Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America

More information

Optimizing Antibiotic Treatment of Skin and Soft Tissue Infections

Optimizing Antibiotic Treatment of Skin and Soft Tissue Infections Optimizing Antibiotic Treatment of Skin and Soft Tissue Infections 15th Annual Rocky Mountain Hospital Medicine Symposium November 6, 2017 Tim Jenkins, MD Director, Antibiotic Stewardship Program Denver

More information

Le infezioni di cute e tessuti molli

Le infezioni di cute e tessuti molli Le infezioni di cute e tessuti molli SCELTE e STRATEGIE TERAPEUTICHE Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Treatment of complicated skin and skin structure infections

More information

Infectious Disease Issues in the Intensive Care Unit

Infectious Disease Issues in the Intensive Care Unit Infectious Disease Issues in the Intensive Care Unit Catherine Liu, M.D. Assistant Clinical Professor Division of Infectious Diseases University of California, San Francisco Overview Emerging antibiotic

More information

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How

More information

One-Hit Wonders: A New Era of Antibiotics?

One-Hit Wonders: A New Era of Antibiotics? One-Hit Wonders: A New Era of Antibiotics? Patrick Wieruszewski, PharmD PGY-1 Pharmacy Resident Pharmacy Grand Rounds November 1, 2016 2016 MFMER slide-1 Objectives Identify advantages and disadvantages

More information

New Antibiotics & New Insights into Old Antibiotics

New Antibiotics & New Insights into Old Antibiotics New Antibiotics & New Insights into Old Antibiotics Louisiana Chapter of the American Academy of Pediatrics August 18, 2018 Baton Rouge, Louisiana John Bradley MD Rady Children s Hospital San Diego University

More information

Discussion Points. Decisions in Selecting Antibiotics

Discussion Points. Decisions in Selecting Antibiotics Antibiotics in Acute Care Fredrick M. Abrahamian, D.O., FACEP, FIDSA Clinical Professor of Medicine UCLA School of Medicine Director of Education Department of Emergency Medicine Olive View-UCLA Medical

More information

CLINICAL USE OF BETA-LACTAMS

CLINICAL USE OF BETA-LACTAMS CLINICAL USE OF BETA-LACTAMS Douglas Black, Pharm.D. Associate Professor School of Pharmacy University of Washington dblack@u.washington.edu WHY IS INFECTIOUS DISEASE PHARMACOTHERAPY SO CONFUSING? Microbial

More information

Choose Your Own Antibiotic/Adventure Gram-Positive Style

Choose Your Own Antibiotic/Adventure Gram-Positive Style Disclosures Consultant for Cubist Pharmaceuticals, Inc Research support from Forest Laboratories Choose Your Own Antibiotic/Adventure Gram-Positive Style I have never seen Star Wars (But I m a big fan

More information

Ca-MRSA Update- Hand Infections. Washington Hand Society September 19, 2007

Ca-MRSA Update- Hand Infections. Washington Hand Society September 19, 2007 Ca-MRSA Update- Hand Infections Washington Hand Society September 19, 2007 Resistant Staph. Aureus Late 1940 s -50% S.Aureus resistant to PCN 1957-80/81 strain- of S.A. highly virulent and easily transmissible

More information

Critical impact of antimicrobial resistance

Critical impact of antimicrobial resistance New Antibiotics Kurt B. Stevenson, MD, MPH Professor of Medicine and Epidemiology Division of Infectious Diseases Department of Internal Medicine The Ohio State University College of Medicine Critical

More information

New Drugs for Bad Bugs- Statewide Antibiogram

New Drugs for Bad Bugs- Statewide Antibiogram New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda

More information

Infectious Disease: Drug Resistance Pattern in New Mexico

Infectious Disease: Drug Resistance Pattern in New Mexico Infectious Disease: Drug Resistance Pattern in New Mexico Are these the world's sexiest accents? Obi C. Okoli, MD.,MPH. Clinic for Infectious Diseases Las Cruces, NM. Are these the world's sexiest accents?

More information

Cigna Drug and Biologic Coverage Policy

Cigna Drug and Biologic Coverage Policy Cigna Drug and Biologic Coverage Policy Subject Oxazolidinone Antibiotics Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5 References... 5 Effective Date...

More information

Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate

Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Cefazolin vs. Antistaphyloccal Penicillins: The Great Debate Annie Heble, PharmD PGY2 Pediatric Pharmacy Resident Children s Hospital Colorado Microbiology Rounds March 22, 2017 Image Source: Buck cartoons

More information

STAPHYLOCOCCI: KEY AST CHALLENGES

STAPHYLOCOCCI: KEY AST CHALLENGES Romney Humphries, PhD D(ABMM) Section Chief, UCLA Clinical Microbiology Los Angeles CA rhumphries@mednet.ucla.edu STAPHYLOCOCCI: KEY AST CHALLENGES THE CHALLENGES detection of penicillin resistance detection

More information

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011

Antibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011 Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond

More information

Rise of Resistance: From MRSA to CRE

Rise of Resistance: From MRSA to CRE Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance

More information

The role of new antibiotics in the treatment of severe infections: Safety and efficacy features

The role of new antibiotics in the treatment of severe infections: Safety and efficacy features The role of new antibiotics in the treatment of severe infections Safety and efficacy features Christian Eckmann Hannover, Germany The role of new antibiotics in the treatment of severe infections: Safety

More information

Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients

Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients Duke University Hospital Guideline for Empiric Inpatient Treatment of Cancer- Related Neutropenic Fever in Adult Patients PURPOSE Fever among neutropenic patients is common and a significant cause of morbidity

More information

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases

Appropriate Management of Common Pediatric Infections. Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases Appropriate Management of Common Pediatric Infections Blaise L. Congeni M.D. Akron Children s Hospital Division of Pediatric Infectious Diseases It s all about the microorganism The common pathogens Viruses

More information

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials

Disclosures. Principles of Antimicrobial Therapy. Obtaining an Accurate Diagnosis Obtain specimens PRIOR to initiating antimicrobials Disclosures Principles of Antimicrobial Therapy None Lori A. Cox MSN, ACNP-BC, ACNPC, FCCM Penn State Hershey Medical Center Neuroscience Critical Care Unit Obtaining an Accurate Diagnosis Determine site

More information

SIVEXTRO (tedizolid phosphate) oral tablet ZYVOX (linezolid) oral suspension and tablet

SIVEXTRO (tedizolid phosphate) oral tablet ZYVOX (linezolid) oral suspension and tablet ZYVOX (linezolid) oral suspension and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This

More information

10/13/14. Low: not well absorbed. Good: [blood and tissue] < than if given IV. High: > 90% absorption orally

10/13/14. Low: not well absorbed. Good: [blood and tissue] < than if given IV. High: > 90% absorption orally Low: not well absorbed PO agent not for serious infection nitrofurantoin Good: [blood and tissue] < than if given IV [Therapeutic] in excess of [effective] eg. cephalexin High: > 90% absorption orally

More information

Necrotizing Soft Tissue Infections: Emerging Bacterial Resistance

Necrotizing Soft Tissue Infections: Emerging Bacterial Resistance Necrotizing Soft Tissue Infections: Emerging Bacterial Resistance Eileen M. Bulger, MD Professor of Surgery Harborview Medical Center University of Washington Objectives Review definition & diagnostic

More information

* gender factor (male=1, female=0.85)

* gender factor (male=1, female=0.85) Usual Doses of Antimicrobials Typically Not Requiring Renal Adjustment Azithromycin 250 500 mg Q24 *Amphotericin B 1 3-5 mg/kg Q24 Clindamycin 600 900 mg Q8 Liposomal (Ambisome ) Doxycycline 100 mg Q12

More information

Evolution of antibiotic resistance. October 10, 2005

Evolution of antibiotic resistance. October 10, 2005 Evolution of antibiotic resistance October 10, 2005 Causes of death, 2001: USA 6. Population: 6,122,210,000 Deaths: 56,554,000 1. Infectious and parasitic diseases: 14.9 million 1. 2. 3. 4. 5. 2. Heart

More information

ANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin

ANTIBIOTICS USED FOR RESISTACE BACTERIA. 1. Vancomicin ANTIBIOTICS USED FOR RESISTACE BACTERIA 1. Vancomicin Vancomycin is used to treat infections caused by bacteria. It belongs to the family of medicines called antibiotics. Vancomycin works by killing bacteria

More information

Antimicrobial Update. Vicky Dudas, Pharm.D. Associate Clinical Professor of Pharmacy Director, Antimicrobial Management Program UCSF Medical Center

Antimicrobial Update. Vicky Dudas, Pharm.D. Associate Clinical Professor of Pharmacy Director, Antimicrobial Management Program UCSF Medical Center Antimicrobial Update Vicky Dudas, Pharm.D. Associate Clinical Professor of Pharmacy Director, Antimicrobial Management Program UCSF Medical Center Objectives Discuss treatment of acute bacterial rhinosinusitis

More information

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES:

More information

Introduction to Pharmacokinetics and Pharmacodynamics

Introduction to Pharmacokinetics and Pharmacodynamics Introduction to Pharmacokinetics and Pharmacodynamics Diane M. Cappelletty, Pharm.D. Assistant Professor of Pharmacy Practice Wayne State University August, 2001 Vocabulary Clearance Renal elimination:

More information

Pharmacology Week 6 ANTIMICROBIAL AGENTS

Pharmacology Week 6 ANTIMICROBIAL AGENTS Pharmacology Week 6 ANTIMICROBIAL AGENTS Mechanisms of antimicrobial action Mechanisms of antimicrobial action Bacteriostatic - Slow or stop bacterial growth, needs an immune system to finish off the microbe

More information

Updates on the Management of Hospital Acquired Infections and Resistant Organisms

Updates on the Management of Hospital Acquired Infections and Resistant Organisms Updates on the Management of Hospital Acquired Infections and Resistant Organisms Kaitlin McGinn, PharmD Assistant Clinical Professor, Critical Care Auburn University, Harrison School of Pharmacy November

More information

Updates on the Management of Hospital Acquired Infections and Resistant Organisms

Updates on the Management of Hospital Acquired Infections and Resistant Organisms Updates on the Management of Hospital Acquired Infections and Resistant Organisms Conflict of Interest I, Kaitlin McGinn, have no actual or potential conflict of interest in relation to this program. Kaitlin

More information

Felipe N. Gutierrez MD, MPH Chief, Infectious Diseases Phoenix VA Healthcare

Felipe N. Gutierrez MD, MPH Chief, Infectious Diseases Phoenix VA Healthcare Felipe N. Gutierrez MD, MPH Chief, Infectious Diseases Phoenix VA Healthcare 100% of all wounds will yield growth If you get a negative culture you something is wrong! Pseudomonas while ubiquitous does

More information

GUIDE TO INFECTION CONTROL IN THE HOSPITAL

GUIDE TO INFECTION CONTROL IN THE HOSPITAL GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 43: Staphylococcus Aureus Authors J. Pierce, MD M. Edmond, MD, MPH, MPA M.P. Stevens, MD, MPH Chapter Editor Michelle Doll, MD, MPH) Topic Outline Key

More information

Getting Smart about Skin Infections and MRSA

Getting Smart about Skin Infections and MRSA Getting Smart about Skin Infections and MRSA Loren G. Miller, M.D., M.P.H. Associate Professor of Medicine David Geffen School of Medicine at UCLA Division of Infectious Diseases Director, Infection Control

More information

Staphylococcus Aureus

Staphylococcus Aureus GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 43: Staphylococcus Aureus Authors J. Pierce, MD M. Edmond, MD, MPH, MPA M.P. Stevens, MD, MPH Chapter Editor Michelle Doll, MD, MPH) Topic Outline Key

More information

Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles

Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Infectious Disease 101: Helping the Consultant Pharmacist with Stewardship Principles Conflicts of Interest None at this time May be discussing off-label indications KALIN M. CLIFFORD, PHARM.D., BCPS,

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

LINEE GUIDA: VALORI E LIMITI

LINEE GUIDA: VALORI E LIMITI Ferrara 28 novembre 2014 LINEE GUIDA: VALORI E LIMITI Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi EVIDENCE BIASED GERIATRIC MEDICINE Older patients with comorbid conditions

More information

GORILLACILLINS IN THE ICU:

GORILLACILLINS IN THE ICU: Conflicts of Interest None to declare GORILLACILLINS IN THE ICU: From SPACE and Beyond... Tim T.Y. Lau, PharmD, FCSHP Clinical Pharmacy Specialist in Infectious Diseases Pharmaceutical Sciences, Vancouver

More information

Beta-lactam antibiotics - Cephalosporins

Beta-lactam antibiotics - Cephalosporins Beta-lactam antibiotics - Cephalosporins Targets - PBP s Activity - Cidal - growing organisms (like the penicillins) Principles of action - Affinity for PBP s Permeability ypropertiesp Stability to bacterial

More information

LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES

LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES INFECTIOUS DISEASE SCARES LEARNING OBJECTIVES ANTIMICROBIAL USES AND ABUSES Goodbye to the Antibiotic Era? Glenn D. Bedsole, MD, FACP Infectious Disease Consultant 1. Be able to list 6 examples of resistant bacteria that present

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

Antibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi

Antibacterial therapy 1. د. حامد الزعبي Dr Hamed Al-Zoubi Antibacterial therapy 1 د. حامد الزعبي Dr Hamed Al-Zoubi ILOs Principles and terms Different categories of antibiotics Spectrum of activity and mechanism of action Resistancs Antibacterial therapy What

More information

Empiric therapy for severe suspected Staphylococcus aureus infection

Empiric therapy for severe suspected Staphylococcus aureus infection Empiric therapy for severe suspected Staphylococcus aureus infection Salman Qureshi, MD McGill University Faculty of Medicine Department of Critical Care Medicine McGill University Health Centre Relevant

More information

HEALTH SERVICES POLICY & PROCEDURE MANUAL

HEALTH SERVICES POLICY & PROCEDURE MANUAL PAGE 1 of 3 PURPOSE To assure that DOP inmates with Soft Tissue Infections are receiving high quality Primary Care for their infections and that the risk of infecting other inmates or staff is minimized.

More information

Source: Portland State University Population Research Center (

Source: Portland State University Population Research Center ( Methicillin Resistant Staphylococcus aureus (MRSA) Surveillance Report 2010 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Health Authority Updated:

More information

Consequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered

Consequences of Antimicrobial Resistant Bacteria. Antimicrobial Resistance. Molecular Genetics of Antimicrobial Resistance. Topics to be Covered Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length

More information

Antibiotic Updates: Part II

Antibiotic Updates: Part II Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures

More information

Intra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018

Intra-Abdominal Infections. Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Intra-Abdominal Infections Jessica Thompson, PharmD, BCPS (AQ-ID) Infectious Diseases Pharmacy Clinical Specialist Renown Health April 19, 2018 Select guidelines Mazuski JE, et al. The Surgical Infection

More information

Methicillin Resistant Staphylococcus Aureus (MRSA) The drug resistant `Superbug that won t die

Methicillin Resistant Staphylococcus Aureus (MRSA) The drug resistant `Superbug that won t die Methicillin Resistant Staphylococcus Aureus (MRSA) The drug resistant `Superbug that won t die Michael A. Miller, MD Assistant Professor of Pediatrics -Jacksonville OBJECTIVES 1. Understand the basic microbiology

More information

MID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance

MID 23. Antimicrobial Resistance. Consequences of Antimicrobial Resistant Bacteria. Molecular Genetics of Antimicrobial Resistance Antimicrobial Resistance Molecular Genetics of Antimicrobial Resistance Micro evolutionary change - point mutations Beta-lactamase mutation extends spectrum of the enzyme rpob gene (RNA polymerase) mutation

More information

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES

4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial

More information

Antimicrobial Resistance

Antimicrobial Resistance Antimicrobial Resistance Consequences of Antimicrobial Resistant Bacteria Change in the approach to the administration of empiric antimicrobial therapy Increased number of hospitalizations Increased length

More information

Antimicrobial Resistance Acquisition of Foreign DNA

Antimicrobial Resistance Acquisition of Foreign DNA Antimicrobial Resistance Acquisition of Foreign DNA Levy, Scientific American Horizontal gene transfer is common, even between Gram positive and negative bacteria Plasmid - transfer of single or multiple

More information

Multi-drug resistant microorganisms

Multi-drug resistant microorganisms Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the

More information

Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance

Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance Robert C Welliver Sr, MD Hobbs-Recknagel Endowed Chair in Pediatrics Chief, Pediatric infectious Diseases Children s Hospital

More information

48 th Annual Meeting. IDWeek and ICAAC: The Cliffs Notes Version. Skin and Soft Tissue Infections. Skin and Soft Tissue Infections.

48 th Annual Meeting. IDWeek and ICAAC: The Cliffs Notes Version. Skin and Soft Tissue Infections. Skin and Soft Tissue Infections. 48 th Annual Meeting IDWeek and ICAAC: The Cliffs Notes Version Yanina Pasikhova Pharm.D., BCPS-AQ ID, AAHIVP Infectious Diseases Pharmacist Moffitt Cancer Center Navigating the Oceans of Opportunity Skin

More information

Overview Management of Skin and Soft Tissue Infections in the MRSA Era

Overview Management of Skin and Soft Tissue Infections in the MRSA Era Overview Management of Skin and Soft Tissue Infections in the MRSA Era April 2011 2011 IDSA MRSA Treatment Guidelines Skin and soft tissue infections (SSTIs) Management of Recurrent SSTIs Necrotizing soft

More information

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority

2019 COLLECTION TYPE: MIPS CLINICAL QUALITY MEASURES (CQMS) MEASURE TYPE: Process High Priority Quality ID #407: Appropriate Treatment of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Bacteremia National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Healthcare Associated

More information

RESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery

RESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,

More information

TACKLING THE MRSA EPIDEMIC

TACKLING THE MRSA EPIDEMIC TACKLING THE MRSA EPIDEMIC Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine MRSA Trend (HA + CA) in US TSN Database USA (1993-2003) % of MRSA among S. aureus

More information

Management of Native Valve

Management of Native Valve Management of Native Valve Infective Endocarditis 2005 AHA 2015 Baddour LM, et al. Circulation. 2015;132(15):1435-86 2009 ESC 2015 Habib G, et al. Eur Heart J. 2015;36(44):3075-128 ESC 2015: Endocarditis

More information

Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems

Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Micro 301 Antimicrobial Drugs 11/7/12 Significance of antimicrobial drugs Challenges Emerging resistance Fewer new drugs MRSA and other resistant pathogens are major problems Definitions Antibiotic Selective

More information

The new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, ): is the future (really) shining?

The new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, ): is the future (really) shining? S. aureus: what do we need to know (and to do) in 2007? The new antistaphylococcal drugs (tigecycline, daptomycin, telavancin, ): is the future (really) shining? Françoise Van Bambeke Unité de Pharmacologie

More information

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University

More information

Antibiotic Stewardship Program (ASP) CHRISTUS SETX

Antibiotic Stewardship Program (ASP) CHRISTUS SETX Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:

More information

MICU Antibiotics and Associated Drug Interactions

MICU Antibiotics and Associated Drug Interactions MICU Antibiotics and Associated Drug Interactions Resistant Bacteria MICU patient are at risk for resistant organisms: Recent hospitalizations From a skilled nursing facility Immunocompromised patients

More information

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck! Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which

More information

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV

Perichondritis: Source: UpToDate Ciprofloxacin 10 mg/kg/dose PO (max 500 mg/dose) BID Inpatient: Ceftazidime 50 mg/kg/dose q8 hours IV Empiric Antibiotics for Pediatric Infections Seen in ED NOTE: Choice of empiric antibiotic therapy must take into account local pathogen frequency and resistance patterns, individual patient characteristics,

More information

Multi-Drug Resistant Organisms (MDRO)

Multi-Drug Resistant Organisms (MDRO) Multi-Drug Resistant Organisms (MDRO) 2016 What are MDROs? Multi-drug resistant organisms, or MDROs, are bacteria resistant to current antibiotic therapy and therefore difficult to treat. MDROs can cause

More information

Standing Orders for the Treatment of Outpatient Peritonitis

Standing Orders for the Treatment of Outpatient Peritonitis Standing Orders for the Treatment of Outpatient Peritonitis 1. Definition of Peritonitis: a. Cloudy effluent. b. WBC > 100 cells/mm3 with >50% polymorphonuclear (PMN) cells with minimum 2 hour dwell. c.

More information

Clindamycin coverage streptococcus

Clindamycin coverage streptococcus Clindamycin coverage streptococcus Oct 12, 2017. While clindamycin and erythromycin were at one time uniformly active against group B streptococci, resistance has been increasing. One large. We assessed

More information

Cell Wall Weakeners. Antimicrobials: Drugs that Weaken the Cell Wall. Bacterial Cell Wall. Bacterial Resistance to PCNs. PCN Classification

Cell Wall Weakeners. Antimicrobials: Drugs that Weaken the Cell Wall. Bacterial Cell Wall. Bacterial Resistance to PCNs. PCN Classification Cell Wall Weakeners Antimicrobials: Drugs that Weaken the Cell Wall Beta Lactams Penicillins Cephalosporins Carbapenems Aztreonam Vancomycin Teicoplanin Bacterial Cell Wall Bacterial cytoplasm is hypertonic

More information

Protein Synthesis Inhibitors

Protein Synthesis Inhibitors Protein Synthesis Inhibitors Assistant Professor Dr. Naza M. Ali 11 Nov 2018 Lec 7 Aminoglycosides Are structurally related two amino sugars attached by glycosidic linkages. They are bactericidal Inhibitors

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium tigecycline 50mg vial of powder for intravenous infusion (Tygacil ) (277/06) Wyeth 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the

More information

HOW TO INTERPRET CULTURE RESULTS. Karen Brust, MD November 29, 2012

HOW TO INTERPRET CULTURE RESULTS. Karen Brust, MD November 29, 2012 HOW TO INTERPRET CULTURE RESULTS Karen Brust, MD November 29, 2012 DISCLOSURES NONE CULTURE RESULTS Based on susceptibility patterns CLSI: international, interdisciplinary, Nonprofit,

More information

Novel therapies & the role of early switch and early discharge protocols for management of MRSA infections

Novel therapies & the role of early switch and early discharge protocols for management of MRSA infections Novel therapies & the role of early switch and early discharge protocols for management of MRSA infections Paul M. Tulkens, MD, PhD Cellular and Molecular Pharmacology & Centre for Clinical Pharmacy Louvain

More information

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid

Clinical Policy: Linezolid (Zyvox) Reference Number: CP.PMN.27 Effective Date: Last Review Date: Line of Business: HIM*, Medicaid Clinical Policy: (Zyvox) Reference Number: CP.PMN.27 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: HIM*, Medicaid Coding Implications Revision Log See Important Reminder at the end

More information

Bad Bugs. Pharmacist Learning Objectives. Antimicrobial Resistance. Patient Case. Pharmacy Technician Learning Objectives 4/8/2016

Bad Bugs. Pharmacist Learning Objectives. Antimicrobial Resistance. Patient Case. Pharmacy Technician Learning Objectives 4/8/2016 Pharmacist Learning Objectives Antimicrobial Resistance Julie Giddens Pharm D, BCPS Infectious Disease Clinical Pharmacist OSF Saint Francis Medical Center Peoria, IL The speaker has no conflicts to disclose

More information

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria

More information

Approach to pediatric Antibiotics

Approach to pediatric Antibiotics Approach to pediatric Antibiotics Gassem Gohal FAAP FRCPC Assistant professor of Pediatrics objectives To be familiar with common pediatric antibiotics o Classification o Action o Adverse effect To discus

More information

Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level. janet hindler

Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level. janet hindler Surveillance for Antimicrobial Resistance and Preparation of an Enhanced Antibiogram at the Local Level janet hindler At the conclusion of this talk, you will be able to Describe CLSI M39-A3 recommendations

More information